GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (FRA:2F5) » Definitions » Net Margin %

Scinai Immunotherapeutics (FRA:2F5) Net Margin % : 6,238.41% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scinai Immunotherapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Scinai Immunotherapeutics's Net Income for the three months ended in Sep. 2024 was €9.42 Mil. Scinai Immunotherapeutics's Revenue for the three months ended in Sep. 2024 was €0.15 Mil. Therefore, Scinai Immunotherapeutics's net margin for the quarter that ended in Sep. 2024 was 6,238.41%.

The historical rank and industry rank for Scinai Immunotherapeutics's Net Margin % or its related term are showing as below:

FRA:2F5' s Net Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 806.2
Current: 806.2


FRA:2F5's Net Margin % is ranked better than
98.01% of 1007 companies
in the Biotechnology industry
Industry Median: -134.57 vs FRA:2F5: 806.20

Scinai Immunotherapeutics Net Margin % Historical Data

The historical data trend for Scinai Immunotherapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Net Margin % Chart

Scinai Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scinai Immunotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -817.05 6,238.41

Competitive Comparison of Scinai Immunotherapeutics's Net Margin %

For the Biotechnology subindustry, Scinai Immunotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Net Margin % falls into.



Scinai Immunotherapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Scinai Immunotherapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-5.96/0
= %

Scinai Immunotherapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=9.42/0.151
=6,238.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics  (FRA:2F5) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Scinai Immunotherapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Headlines

No Headlines